Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Tenaya Therapeutics, Inc.

Tenaya Therapeutics is a clinical stage biotechnology company. The Company was founded in 2016 by leading cardiovascular scientists from the David J. Gladstone Institutes and the University of Texas Southwestern Medical Center.

We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver curative therapies that address the underlying drivers of heart disease. Our vision is to change the treatment paradigm for heart disease, and in doing so improve and extend the lives of millions of individuals and families fighting this debilitating disease. We are advancing a pipeline of disease-modifying therapies developed using our product platforms and core internal capabilities to target defined sub-populations of patients with rare or highly prevalent forms of heart disease.

The Column Group

Casdin Capital

Greenspring Associates

RTW Investments

Fidelity Management and Research Company

Google Ventures

T. Rowe Price

RA Capital Management

Tenaya Therapeutics

Wishing safe and happy holidays to our team, our partners, our friends and families and the entire Tenaya community. See you in the new year!

Pioneering the field of genetic medicines for heart disease requires some serious creativity in addition to scientific chops, and this month our Cardiovascular Genetics team showed off their fun side with a mustache-growing contest. Looking good, team. We can't wait to see what you'll do next!

Along with our partners at the DCM Foundation, Tenayans Wendy Borsari, Senior Manager of Patient Advocacy, and Jeff Haroldson, Executive Director of Medical Affairs, will present an informative webinar about genetics, gene therapies and clinical trials for cardiomyopathy today, Dec. 13 from 6:00-7:00 PM ET. 
  
Register here: bit.ly/3QMFCC0  
  
#heartdisease #PatientsFirst #GeneTherapy

Every year before the holidays, we add notes of appreciation to our Tenaya Tree of Thankfulness and watch it grow with the kind words of gratitude we share for each other. This year, we built on our tradition and got together for a special Friendsgiving potluck lunch too. We're thankful to be #OneTenaya!

Today, Tenaya CEO Faraz Ali will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference. Read our press release for more details: https://bit.ly/47OHlxx

Team Tenaya came together in celebration of Diwali, the festival of lights, this month. Our gathering was filled with laughter, good food and great company. Check out these photos of the team! #YouLead #Community #OneTenaya

Curious about the role of gene therapy in cardiomyopathy? We’re partnering with the DCM Foundation to present an informative webinar about genetics, gene therapies and clinical trials for cardiomyopathy on Wednesday, Dec. 13 from 6:00-7:00 PM ET.
 
Wendy Borsari, Senior Manager of Patient Advocacy, and Jeff Haroldson, Executive Director of Medical Affairs, from Tenaya will speak to a range of topics and our hopes for the future of gene therapies for the heart. Click here to register and learn more: bit.ly/3QMFCC0
 
#heartdisease #PatientsFirst #GeneTherapy

Happy Genetic Counselor Awareness Day! Tenaya recognizes the important work genetic counselors do in clinics, labs, hospitals and research to help people better understand their health, make informed healthcare decisions, and shape the future of personalized medicine. Learn more about genetic counselors: https://bit.ly/3Bi7yo8

Yesterday, we announced our Q3 earnings and business highlights - including the receipt of Fast Track designation for TN-401. See below for the top headlines! Read the full press release: https://bit.ly/3ua1mA9 #heartdisease #biotechnews

The latest #OneTenaya G&A #teambuilder brought the group to The Walt Disney Family Museum in San Francisco. The team learned that the journey from the creation of Disney to what it is today holds many parallels to the #biotech industry – there are setbacks, but a common vision and perseverance prevails. 

Thank you to the Museum for hosting us!

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	600K -	1.02M 69.50%	10.72M 954.18%	9.58M 10.66%	5.63M 41.22%
accumulated other comprehensive income loss			-141K -	-378K 168.09%	-106K 71.96%
cash and cash equivalents	23.87M -	128.53M 438.43%	38.13M 70.34%	95.27M 149.87%	45.68M 52.05%
cash and short term investments	26.63M -	128.53M 382.76%	251.30M 95.51%	204.23M 18.73%	104.64M 48.76%
common stock			4K -	7K 75%	7K 0%
deferred revenue			8.90M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt			13.71M -	11.09M 19.07%	8.11M 26.94%
long term investments				17.70M -
net debt	-23.87M -	-128.53M 438.43%	-24.42M 81.00%	-80.17M 228.28%	-33.26M 58.52%
net receivables
other assets
other current assets			4.06M -	7.23M 78.09%	6.94M 3.97%
other current liabilities	3.52M -	4.02M 14.32%	162K 95.97%	10.66M 6,482.72%	12.78M 19.88%
other liabilities				243.38M -
other non current assets	684K -	1.01M 47.95%	4.13M 307.71%	4.79M 16.17%	5.68M 18.44%
other non current liabilities	77.62M -	224.44M 189.15%	182K 99.92%	228K 25.27%	253K 10.96%
othertotal stockholders equity	678K -	1.50M 120.80%	120.01M 7,916.50%	522.95M 335.76%	542.80M 3.80%
preferred stock			314.19M -
property plant equipment net	9.57M -	17.18M 79.48%	54.70M 218.33%	62.70M 14.61%	53.26M 15.06%
retained earnings	-44.42M -	-82.81M 86.44%	-155.53M 87.81%	-279.20M 79.51%	-403.28M 44.44%
short term debt			1.99M -	4.01M 100.90%	4.32M 7.81%
short term investments	2.75M -		213.17M -	91.25M 57.19%	58.96M 35.39%
tax assets
tax payables
total assets	38.00M -	148.16M 289.89%	314.19M 112.06%	278.94M 11.22%	170.51M 38.87%
total current assets	27.74M -	129.96M 368.47%	255.36M 96.48%	193.75M 24.12%	111.58M 42.41%
total current liabilities	4.12M -	5.04M 22.35%	21.77M 331.94%	24.25M 11.36%	22.73M 6.25%
total debt			13.71M -	15.10M 10.16%	12.42M 17.72%
total investments	2.75M -		213.17M -	108.96K 99.95%	58.96M 54,013.51%
total liabilities	81.74M -	229.48M 180.74%	35.66M 84.46%	278.94M 682.17%	31.09M 88.85%
total liabilities and stockholders equity	38.00M -	148.16M 289.89%	314.19M 112.06%	278.94M 11.22%	170.51M 38.87%
total non current assets	10.26M -	18.20M 77.38%	58.83M 223.30%	85.19M 44.81%	58.93M 30.82%
total non current liabilities	77.62M -	224.44M 189.15%	13.89M 93.81%	11.32M 18.49%	8.36M 26.17%
total stockholders equity	-43.74M -	-81.31M 85.91%	278.53M 442.53%	243.38M 12.62%	139.42M 42.71%

NASDAQ:TNYA

Tenaya Therapeutics

Last Close

2.77

30/08 20:00

Market Cap

241.05M

Beta: -

Volume Today

257.84K

Avg: 560.72K

PE Ratio

−2.55

PFCF: −2.80

Preview